Is Krystal Biotech, Inc.'s (NASDAQ:KRYS) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Is Krystal Biotech, Inc.'s (NASDAQ:KRYS) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Krystal Biotech (NASDAQ:KRYS) has had a great run on the share market with its stock up by a significant 18% over the last three months. Given that stock prices are usually aligned with a company's financial performance in the long-term, we decided to study its financial indicators more closely to see if they had a hand to play in the recent price move. Particularly, we will be paying attention to Krystal Biotech's ROE today.
Krystal biotech(納斯達克:KRYS)近三個月來的股市表現良好,其股票上漲了顯著的18%。由於股價通常與公司的長期財務表現一致,因此我們決定更仔細地研究其財務指標,以確定它們是否對最近價格的變動有所作爲。尤其是,我們將關注Krystal biotech今天的ROE。
ROE or return on equity is a useful tool to assess how effectively a company can generate returns on the investment it received from its shareholders. In short, ROE shows the profit each dollar generates with respect to its shareholder investments.
roe或權益回報率是評估公司有效利用股東投資產生回報效率的有用工具。簡而言之,roe顯示每個股東投資所產生的利潤。
How Is ROE Calculated?
淨資產收益率怎麼計算?
The formula for return on equity is:
權益回報率的計算公式是:
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
淨資產收益率 = 淨利潤(從持續經營中獲得)÷ 股東權益
So, based on the above formula, the ROE for Krystal Biotech is:
所以,根據上述公式,Krystal biotech的ROE爲:
13% = US$106m ÷ US$839m (Based on the trailing twelve months to June 2024).
13%=美元1.06億÷美元8.39億(基於截至2024年6月的過去12個月)。
The 'return' is the profit over the last twelve months. Another way to think of that is that for every $1 worth of equity, the company was able to earn $0.13 in profit.
「回報」是過去12個月的利潤。另一種考慮方法是,對於每1美元的股權,公司能夠賺取0.13美元的利潤。
Why Is ROE Important For Earnings Growth?
ROE爲什麼對淨利潤增長很重要?
So far, we've learned that ROE is a measure of a company's profitability. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics.
到目前爲止,我們已經了解到roe是公司盈利能力的一種衡量標準。根據公司選擇重新投資或「留存」的利潤比例,我們能夠評估公司未來產生利潤的能力。其他條件不變的情況下,roe和盈利留存越高,相較於不具備這些特徵的公司,企業的增長率越高。
Krystal Biotech's Earnings Growth And 13% ROE
Krystal biotech的盈利增長和ROE爲13%。
To start with, Krystal Biotech's ROE looks acceptable. Yet, the fact that the company's ROE is lower than the industry average of 16% does temper our expectations. Further, Krystal Biotech's five year net income growth of -0.4% is more or less flat. Bear in mind, the company does have a respectable level of ROE. It is just that the industry ROE is higher. Therefore, the flat earnings growth could be the result of other factors. For example, it could be that the company has a high payout ratio or the business has alloacted capital, for instance.
首先,Krystal biotech的ROE看起來是可以接受的。但是,公司的ROE低於行業平均水平16%的事實確實會降低我們的期望值。此外,Krystal biotech的五年淨利潤增長率爲-0.4%,幾乎保持不變。請記住,公司確實有一個可觀的ROE水平。只是行業ROE更高。因此,持平的盈利增長可能是其他因素的結果。例如,可能是公司具有較高的派息比率或業務分配了資本等原因導致的。
Next, on comparing with the industry net income growth, we found that the industry grew its earnings by 19% over the last few years.
接下來,與行業的淨收入增長相比,我們發現行業在過去幾年中實現了19%的收入增長。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240811/0-310b6199798470d2eb81de03161d710f-0-85229161ebc6825cdfeaf35cf22bd10f.png/big)
The basis for attaching value to a company is, to a great extent, tied to its earnings growth. It's important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. One good indicator of expected earnings growth is the P/E ratio which determines the price the market is willing to pay for a stock based on its earnings prospects. So, you may want to check if Krystal Biotech is trading on a high P/E or a low P/E, relative to its industry.
爲公司賦值的基礎在很大程度上與其盈利增長有關。投資者了解市場是否已經定價了公司預期的盈利增長(或下降)至關重要。通過這樣做,他們會知道股票是進入純淨的藍色水域還是等待泥濘的水域。預期收益增長的一個良好指標是P/E比率,根據其盈利前景確定市場願意爲股票支付的價格。因此,您可能需要檢查Krystal biotech與行業相比是高PE還是低PE的交易價格。
Is Krystal Biotech Efficiently Re-investing Its Profits?
Krystal biotech是否高效地再投資其利潤?
Krystal Biotech doesn't pay any regular dividends, meaning that the company is keeping all of its profits, which makes us wonder why it is retaining its earnings if it can't use them to grow its business. So there might be other factors at play here which could potentially be hampering growth. For example, the business has faced some headwinds.
Krystal biotech沒有支付任何正常的股息,這意味着該公司正在保留其所有利潤,這讓我們想知道,如果無法利用利潤來增長業務,爲什麼要保留其利潤。因此,可能有其他因素在起作用,這可能會妨礙增長。例如,業務遇到了一些阻力。
Summary
總的來說,我們對偉明環保的表現非常滿意。具體而言,我們喜歡公司以高回報率再投資了其利潤的很大一部分。當然,這導致公司的收益大幅增長。但是,最新的行業分析師預測表明,該公司的收益預計將加速增長。
Overall, we feel that Krystal Biotech certainly does have some positive factors to consider. Yet, the low earnings growth is a bit concerning, especially given that the company has a respectable rate of return and is reinvesting a huge portion of its profits. By the looks of it, there could be some other factors, not necessarily in control of the business, that's preventing growth. Having said that, looking at current analyst estimates, we found that the company's earnings growth rate is expected to see a huge improvement. To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more.
總的來說,我們認爲Krystal biotech確實具有一些正面因素需要考慮。但是,低盈利增長有點令人擔憂,特別是考慮到公司具有可觀的回報率,並且正在重新投資其利潤的巨大部分。看起來,可能有其他因素在起作用,而不一定是業務能夠控制。話雖如此,查看當前分析師的估計,我們發現公司的盈利增長率預計將有顯着改善。欲知更多有關公司未來盈利增長預測的信息,請查看有關分析師預測的免費報告。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。